GW Pharmaceuticals plc (NASDAQ:GWPH) said Monday that the results of the company’s positive Phase 3 clinical trial of Epidiolex oral solution in seizures related to tuberous sclerosis complex were published in JAMA Neurology.
Epidiolex is the first FDA-authorized CBD medicine for treating children with severe forms of epilepsy. The medicine was first approved for treatments of seizures connected to Lennox-Gastaut syndrome and Dravet syndrome.
Tuberous sclerosis complex is a genetic condition that causes the growth of tumors, usually benign ones, in vital organs, further causing genetic epilepsy.
Around 1 million people in the world suffer from the condition, which causes various types of seizures.
Noema Pharma AG, a Basel, Switzerland-based clinical-stage company targeting orphan neurological disorders, raised a Series A financing round, raising CHF54m ($59m USD).
The round was co-led by Sofinnova Partners and Polaris Partners with participation from new international investors Gilde Healthcare, Invus and BioMed Partners. Roche, the Swiss multinational healthcare company, received a shareholding in Noema in exchange for rights to four clinical-stage product-candidates. In conjunction with the funding, Darren Carroll of Polaris Partners and Arthur Franken of Gilde Healthcare joined Antoine Papiernik of Sofinnova Partners on the Board of Directors.
The company intends to use the funds to further develop its clinical-stage pipeline. The product candidates will be developed in neurological indications with severe unmet need, such as seizures in tuberous sclerosis complex (TSC), trigeminal neuralgia, Tourette syndrome and other rare neurological disorders.